

Fund Fact Sheet
Fund Overview

Base Currency for Fund	USD
Total Net Assets (USD)	2,42 billion
Fund Inception Date	03.04.2000
Number of Issuers	108
Benchmark	NASDAQ Biotechnology Index
Morningstar Category™	Other Equity

Summary of Investment Objective

The Fund aims to achieve capital appreciation by investing principally in equity securities of biotechnology companies and discovery research firms mainly located in the US.

Fund Management


Evan McCulloch, CFA: United States
 Wendy Lam, PhD: United States
 Akiva Felt: United States

Asset Allocation


	%
Equity	91,94
Cash & Cash Equivalents	8,06

Performance
Performance over 3 Years in Share Class Currency (%)

■ Franklin Biotechnology Discovery Fund A (acc) EUR-H1 ■ NASDAQ Biotechnology Index in USD


Discrete Annual Performance in Share Class Currency (%)

	04/20	04/19	04/18	04/17	04/16
	04/21	04/20	04/19	04/18	04/17
A (acc) EUR-H1	22,54	14,27	-5,57	N/A	N/A
Benchmark in USD	24,75	16,66	2,71	N/A	N/A

Performance in Share Class Currency (%)

	Cumulative					Annualised		
	1 Mth	3 Mths	6 Mths	1 Yr	3 Yrs	Since Incept	3 Yrs	Since Incept
A (acc) EUR-H1	0,67	-4,51	10,08	22,54	32,23	35,40	9,76	10,39
Benchmark in USD	2,97	-3,78	18,73	24,75	49,48	53,17	14,34	14,92

Past performance is not an indicator or a guarantee of future performance. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. Performance details provided are in share class currency, net income reinvested, gross of tax, net of management fees. Sales charges and other commissions, other taxes and relevant costs to be paid by an investor are not included in the calculations. Performance may also be affected by currency fluctuations. Up to date performance figures can be found on our local website.

The share class shown has adopted a hedging strategy intended to reduce the effect of exchange rate movements between the currency of the Fund's investment strategy and the currency of the share class. The benchmark returns displayed are shown in the reference currency of the Fund's investment strategy (USD), while share class returns are shown in the reference currency of share class (EUR). As a result, the returns shown above reflect the effect of the hedging strategy and one can compare the returns of the Fund (net of fees) relative to its benchmark index without the impact of exchange rate movements on index returns.

Top Ten Holdings (% of Total)

Issuer Name	%
GILEAD SCIENCES INC	6,05
AMGEN INC	5,24
REGENERON PHARMACEUTICALS INC	4,56
VERTEX PHARMACEUTICALS INC	4,12
ILLUMINA INC	4,07
NOVAVAX INC	3,66
HORIZON PHARMA PLC	3,54
BIOGEN INC	3,05
IOVANCE BIOTHERAPEUTICS INC	2,98
MIRATI THERAPEUTICS INC	2,41

Fund Measures

P/E to Growth	1,72x
Historical 3 Yr Sales Growth	46,53%
Estimated 3-5 Yr EPS Growth	8,77%
Price to Earnings (12-mo Forward)	14,00x
Standard Deviation (3 Yrs)	23,76%

Share Class Information (For a full list of available share classes, please visit your local website)

Share Class	Incept Date	NAV	TER (%)	Fees	Dividends	Fund Identifiers			
				Max. Annual Charge (%)	Last Paid Date	Last Paid Amount	Bloomberg ID	ISIN	SEDOL
A (acc) EUR-H1	06.04.2018	EUR 13,54	1,83	1,50	N/A	N/A	FTBAEH1 LX	LU1803069274	BFXW2Q7

Composition of Fund

Market Capitalisation Breakdown in USD	% of Equity
<2,0 Billion	22,33
2,0-5,0 Billion	18,59
5,0-10,0 Billion	15,61
10,0-25,0 Billion	9,89
25,0-50,0 Billion	5,68
>50,0 Billion	27,23
N/A	0,68

What Are the Key Risks?

The value of shares in the Fund and income received from it can go down as well as up and investors may not get back the full amount invested. Performance may also be affected by currency fluctuations. Currency fluctuations may affect the value of overseas investments. The Fund invests mainly in equity securities of biotechnology companies. Such securities have historically been subject to significant price movements that may occur suddenly due to market, sector or company-specific factors. As a result, the performance of the Fund can fluctuate very significantly over relatively short time periods. Other significant risks include: securities lending risk, equity risk. For full details of all of the risks applicable to this Fund, please refer to the "Risk Considerations" section of the Fund in the current prospectus of Franklin Templeton Investment Funds.

Important Information

Given the variety of investment options available today, we suggest investors seek guidance from a Financial Adviser.

This document is intended to be of general interest only and does not constitute legal or tax advice nor is it an offer for shares or invitation to apply for shares of the Franklin Templeton Investment Funds (the Fund). Nothing in this document should be construed as investment advice.

Opinions expressed are the author's at publication date and they are subject to change without prior notice. **The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. Past performance is not an indicator or a guarantee of future performance.** Currency fluctuations may affect the value of overseas investments. When investing in a fund denominated in a foreign currency, your performance may also be affected by currency fluctuations. An investment in the Fund entails risks which are described in the Fund's prospectus and the relevant Key Investor Information Document. In emerging markets, the risks can be greater than in developed markets. Investments in derivative instruments entail specific risks that may increase the risk profile of the fund and are more fully described in the Fund's prospectus and in the relevant Key Investor Information Document. No shares of the Fund may be directly or indirectly offered or sold to residents of the United States of America. Any research and analysis contained in this document has been procured by Franklin Templeton for its own purposes and is provided to you only incidentally. References to particular industries, sectors or companies are for general information and are not necessarily indicative of a fund's holding at any one time.

Please consult your financial advisor before deciding to invest. Subscriptions to shares of the Fund can only be made on the basis of the current prospectus, the relevant Key Investor Information Document, accompanied by the latest available audited annual report and the latest semi-annual report if published thereafter. These documents can be obtained, free of charge from Franklin Templeton International Services S.á.r.l. (FTIS), Swedish branch filial, Nybrokajen 5, SE-111 48 Stockholm, Sweden. Phone: +46 (0) 8 545 01230, Fax: +46 (0) 8 545 01239, E-mail: nordicinfo@franklintempleton.com or can be found on our website www.franklintempletonnordic.com or www.ftidocuments.com. Issued by Franklin Templeton International Services S.á.r.l. (FTIS). FTIS is authorised and regulated in the Luxembourg by the Commission de Surveillance du Secteur Financier and is authorised to conduct certain financial services in the European Economic Area including Denmark, Sweden, Norway, Iceland and Finland.

Source for data and information provided by Franklin Templeton, as of the date of this document, unless otherwise noted. Benchmark related data provided by FactSet, as of the date of this document, unless otherwise noted. References to indices are made for comparative purposes only and are provided to represent the investment environment existing during the time periods shown. An index is unmanaged and one cannot invest directly in an index. The performance of the index does not include the deduction of expenses and does not represent the performance of any Franklin Templeton fund.

When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark.

The Fund invests in a specific sector or geographical area and the returns may be more volatile than a more diversified fund.

Fund Management: CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

Top Ten Holdings: These securities do not represent all of the securities purchased, sold or recommended for clients, and the reader should not assume that investment in the securities listed was or will be profitable. The portfolio manager for the Fund reserves the right to withhold release of information with respect to holdings that would otherwise be included in the top holdings list. For a free copy of the latest prospectus, the relevant Key Investor Information Document, the annual report and semi-annual report, if published thereafter or for more information about any Franklin Templeton fund, contact Franklin Templeton International Services S.á.r.l. (FTIS), Swedish branch filial, Nybrokajen 5, SE-111 48 Stockholm, Sweden. Phone: +46 (0) 8 545 01230, Fax: +46 (0) 8 545 01239, E-mail: nordicinfo@franklintempleton.com or can be found on our website www.franklintempletonnordic.com or www.ftidocuments.com. Issued by Franklin Templeton International Services S.á.r.l. (FTIS). FTIS is authorised and regulated in the Luxembourg by the Commission de Surveillance du Secteur Financier and is authorised to conduct certain financial services in the European Economic Area including Denmark, Sweden, Norway, Iceland and Finland.